Clinical trials: Cystic Fibrosis Pulmonary Exacerbation
Alzheimer Disease, Late Onset, Stroke
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
Since September 1st, 2009, Taiwan has begun to pay attention to the care of patients with organ failure, dementia and the elderly, and brought eight of non-cancer terminal patients into health insurance subsidies to implement the…
- Conditions
- Alzheimer Disease, Late Onset, Stroke, Heart Failure, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT05407272
- Testing
- Health Education Manual, manual
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wen-Shiou Pan
Cystic Fibrosis
PEP and OPEP Devices in Cystic Fibrosis
Cystic fibrosis (CF) is the most common severe autosomal recessive genetic disease in Caucasians. The CFTR (cystic fibrosis transmembrane regulator) gene, which encodes the chloride channel of the epithelial cell membrane, is…
- Trial name
- NCT05801952
- Testing
- Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Cystic Fibrosis
Muco Smartphone Exacerbation
Exacerbation in cystic fibrosis play an important role in terms of mortality and morbidity. Exacerbation frequencies is relatedto FEV1 decline and mortality.
- Trial name
- MUSE (NCT02122289)
- Testing
- Application of Smartphone, No application Smartphone
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis (CF), Cystic Fibrosis Pulmonary Exacerbation
Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis
The CF-Tracker study is a community surveillance study, designed to understand the causes of exacerbations in people with cystic fibrosis (CF) (pwCF).
- Trial name
- CF-Tracker (NCT06940531)
- Where
- 18 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Alexander Horsley
Cystic Fibrosis, Primary Ciliary Dyskinesia
Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia
The objective of this study is to compare the lower airways inflammatory response to infection/pulmonary exacerbation among children known to have Primary Ciliary Dyskinesia (PCD) with children known to have Cystic Fibrosis (CF)…
- Trial name
- NCT01155115
- Testing
- Sputum Collection, Pulmonary Function Testing, Exhaled Nitric Oxide
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- The Hospital for Sick Children
Cystic Fibrosis
18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients
The purpose of this study is to determine if 18Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging can detect changes in airways inflammation in Cystic Fibrosis (CF) patients after treatment for a pulmonary…
- Trial name
- NCT00684346
- Testing
- 18-FDG
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Vitamin D Deficiency, Cystic Fibrosis
Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF
Cystic fibrosis (CF) is an autosomal recessive disease caused by alterations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, characterized by multisystemic alterations, mainly in the lung, intestine…
- Conditions
- Vitamin D Deficiency, Cystic Fibrosis, Bone Density, Low, Inflammation Chronic
- Trial name
- NCT05276960
- Testing
- Cholecalciferol Pill
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Hospital Infantil de Mexico Federico Gomez
Cystic Fibrosis, Cystic Fibrosis in Children
Program Of Exercises During The Hospitalization Of Children And Adolescents With Cystic Fibrosis
The objective of this study was to evaluate the effect of a physical exercise program on the functional capacity of children and adolescents with cystic fibrosis hospitalized at the Hospital de Clínicas of Porto Alegre (HCPA)…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis in Children, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis With Exacerbation
- Trial name
- NCT03273959
- Testing
- Exercise protocol
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Cystic Fibrosis Pulmonary Exacerbation
Glucose Monitoring in Youth With Cystic Fibrosis During Pulmonary Exacerbations
The goal of this study is to investigate the prevalence of dysglycemia with continuous glucose monitoring (CGM) obtained during pulmonary exacerbations, both outpatient and inpatient, in youth with cystic fibrosis (CF).
- Trial name
- GeM-PEx (NCT06546943)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis
Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation
Clinical and translational research in cystic fibrosis (CF) is hampered by a lack of biomarkers that can be used to identify promising new therapies.
- Trial name
- NCT00788359
- Where
- 5 sites in United States
- Volunteers
- 123 people
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs.
- Trial name
- PIPE-CF (NCT01694069)
- Testing
- Piperacillin-tazobactam combination product
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- West Virginia University
Cystic Fibrosis, Impaired Glucose Tolerance
Cystic Fibrosis (CF) Exacerbation and Insulin Treatment
The purpose of the study is to evaluate whether insulin treatment during pulmonary exacerbation (PE) in patients with Cystic Fibrosis (CF)and normoglycemia improves their short term outcome by normalizing the glycemic profile and…
- Conditions
- Cystic Fibrosis, Impaired Glucose Tolerance, Pulmonary Exacerbation
- Trial name
- NCT01149005
- Testing
- novorapid / humalog short acting insulin, Novo Rapid Insulin (Novonordisk)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Hadassah Medical Organization
Cystic Fibrosis
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient…
- Trial name
- STOP PEDS RCT (NCT06654752)
- Testing
- Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
- Where
- 33 sites in United States, Canada
- Volunteers
- 430 people
- Sponsor
- University of Washington, the Collaborative Health Studies Coordinating Center
Cystic Fibrosis
Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis
A phase IV clinical trial, multicentric (3 Hospitals in Madrid) controlled, prospective, open and randomized of long-term treatment with hypertonic saline in cystic fibrosis patients.
- Trial name
- NCT01377792
- Testing
- Hypertonic saline
- Where
- Spain
- Volunteers
- 71 people
- Sponsor
- Adelaida Lamas Ferreiro
Cystic Fibrosis, Lung Infection
Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF
The goal of this research study is to better understand current treatment practices for pulmonary exacerbations (lung infections) and whether the Cystic Fibrosis National Patient Registry (CFFNPR)can be used for this type of…
- Conditions
- Cystic Fibrosis, Lung Infection, Cystic Fibrosis Pulmonary Exacerbation
- Trial name
- STOP-OB-13 (NCT02109822)
- Where
- 12 sites in United States
- Volunteers
- 220 people
- Sponsor
- University of Washington
Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
The purpose of this trial is to compare the effects of treatment with tobramycin solution for inhalation (TIS) with and without azithromycin in people with cystic fibrosis (CF) age 6 months to 18 years who have early isolation of…
- Trial name
- OPTIMIZE (NCT02054156)
- Testing
- azithromycin, Tobramycin solution for inhalation
- Where
- 45 sites in United States
- Volunteers
- 221 people
- Sponsor
- Bonnie Ramsey
Cystic Fibrosis
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older.
- Trial name
- NCT03451045
- Testing
- Lenabasum 20 mg, Lenabasum 5 mg
- Where
- 105 sites in United States, Austria and 19 more
- Volunteers
- 447 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
This study will evaluate the efficacy and safety of an oral ARV-1801(ACG-701) plus optimized background therapy (OBT) compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with Cystic…
- Trial name
- REPRIEVE (NCT05641298)
- Testing
- Sodium Fusidate
- Where
- 25 sites in United States
- Sponsor
- Aceragen
Cystic Fibrosis, Airway Clearance Impairment
IPV vs CPT for Airway Clearance During CF Exacerbation
Intrapulmonary Percussive Ventilation (IPV) will show greater improvements in Forced Expiatory Volume in 1 second (FEV1) shorter duration of stay, and greater time to next pulmonary exacerbation in pediatric Cystic Fibrosis…
- Trial name
- NCT03261219
- Testing
- Intrapulmonary Percussive ventilation, Chest Physiotherapy Vest (Incourage)
- Sponsor
- University of Florida
Cystic Fibrosis
e-Health Program to Prevent Exacerbations in the Cystic Fibrosis Population
The goal of this clinical trial is to analyse the impact of a telematic assessment and monitoring protocol in people with cystic fibrosis, in order to identify exacerbations early, thus preventing loss of lung function and…
- Trial name
- NCT06313827
- Testing
- Exercise plus Monitoring Group (TG-2), Exercise plus monitoring and follow-up group (TGF-3), Exercise Group (CG-1)
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- University of Valencia